Aquestive therapeutics reports positive topline data from part 1 of epiphast trial evaluating aqst-109 epinephrine oral film

Warren, n.j., feb. 25, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced positive topline results from part 1 of the epiphast study for its aqst-109 epinephrine oral film. part 1 showed that key pharmacokinetic measures were aligned with previous favorable results for aqst-109 and that the product was well tolerated with no serious adverse events. a lead candidate is currently being evaluated in part 2 of the epiphast study.
AQST Ratings Summary
AQST Quant Ranking